<DOC>
	<DOC>NCT00054886</DOC>
	<brief_summary>The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.</brief_summary>
	<brief_title>Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer. The patient's kidney cancer must have gotten worse during/after previous cytokinebased therapy was given. Any side effects from prior therapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function Prior treatment with any systemic therapy other than 1 prior cytokinebased treatment regimen; Prior surgical resection of or irradiation to the only site of measurable disease; Ongoing severe hematuria; Other active second malignancy; Cardiovascular diseases or conditions within the last 12 months; Known brain metastases; Known HIVpositive or AIDSrelated illness; Pregnant or breastfeeding women; Current participation in other clinical trials; Other severe acute or chronic medical conditions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>